PDS Biotechnology (PDSB) Total Current Liabilities (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Total Current Liabilities came in at $9.5 million in Q4 2025, down 44.5% YoY from $17.1 million in Q4 2024, and down 28.86% on a QoQ basis from $13.3 million in Q3 2025.
PDS Biotechnology (PDSB) Total Current Liabilities (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Total Current Liabilities data on file, last reported at $9.5 million in Q4 2025.
- Quarterly Total Current Liabilities fell 44.5% year-over-year to $9.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.5 million (down 44.5% YoY) and the FY2025 annual result came in at $9.5 million, down 44.5% from the prior year.
- Total Current Liabilities declined to $9.5 million in Q4 2025, from $13.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $18.3 million in Q3 2024 to a low of $2.9 million in Q1 2021.
- A 5-year average of $9.6 million and a median of $9.3 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 264.78% — and 2025, when it sank 44.5%.
- Tracing PDSB's Total Current Liabilities over 5 years: stood at $3.8 million in 2021, then soared by 161.47% to $9.8 million in 2022, then jumped by 38.78% to $13.6 million in 2023, then climbed by 25.36% to $17.1 million in 2024, then sank by 44.5% to $9.5 million in 2025.
- The last three Total Current Liabilities figures came in at $9.5 million (Q4 2025), $13.3 million (Q3 2025), and $11.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.38 Mn |
| Dec 31, 2025 | 9.48 Mn |
| Sep 30, 2025 | 13.33 Mn |
| Jun 30, 2025 | 11.53 Mn |
| Mar 31, 2025 | 18.27 Mn |
| Dec 31, 2024 | 17.09 Mn |
| Sep 30, 2024 | 18.34 Mn |
| Jun 30, 2024 | 15.67 Mn |
| Mar 31, 2024 | 15.06 Mn |
| Dec 31, 2023 | 13.63 Mn |
| Sep 30, 2023 | 9.15 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 4.13 Mn |
| Dec 31, 2022 | 9.82 Mn |
| Sep 30, 2022 | 4.84 Mn |
| Jun 30, 2022 | 4.52 Mn |
| Mar 31, 2022 | 5.02 Mn |
| Dec 31, 2021 | 3.76 Mn |
| Sep 30, 2021 | 3.58 Mn |
| Jun 30, 2021 | 4.00 Mn |